ARL4C and diffuse large B-cell lymphoma: Notably, high ARL4C expression demonstrated positive associations with immune pathways across plenty of tumors, including KICH, PRAD, THCA, rectum adenocarcinoma (READ), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), sarcoma (SARC), BRCA, and BLCA, among others.